NASDAQ:ABUS Arbutus Biopharma (ABUS) Stock Price, News & Analysis $3.85 +0.02 (+0.52%) (As of 09/30/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends About Arbutus Biopharma Stock (NASDAQ:ABUS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Arbutus Biopharma alerts:Sign Up Key Stats Today's Range$3.79▼$3.9050-Day Range$3.51▼$4.5652-Week Range$1.69▼$4.72Volume670,076 shsAverage Volume1.74 million shsMarket Capitalization$726.80 millionP/E RatioN/ADividend YieldN/APrice Target$5.25Consensus RatingBuy Company OverviewArbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.Read More… Does Elon Musk control the U.S. gov’t? (Ad)Elon has been advising the government to reopen America’s nuclear facilities for years, and now, with the help of Biden’s ADVANCE act, these facilities are once again going back online just as he requested. One company is poised to benefit from America’s nuclear revival like no other. Elon Musk is one of the few people who knows this.Watch this new documentary and you’ll discover what Elon knows, Arbutus Biopharma Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks47th Percentile Overall ScoreABUS MarketRank™: Arbutus Biopharma scored higher than 47% of companies evaluated by MarketBeat, and ranked 668th out of 1,003 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingArbutus Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageArbutus Biopharma has only been the subject of 2 research reports in the past 90 days.Read more about Arbutus Biopharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Arbutus Biopharma are expected to grow in the coming year, from ($0.38) to ($0.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arbutus Biopharma is -8.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arbutus Biopharma is -8.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArbutus Biopharma has a P/B Ratio of 6.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Arbutus Biopharma's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.47% of the outstanding shares of Arbutus Biopharma have been sold short.Short Interest Ratio / Days to CoverArbutus Biopharma has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in Arbutus Biopharma has recently increased by 8.25%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArbutus Biopharma does not currently pay a dividend.Dividend GrowthArbutus Biopharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.47% of the outstanding shares of Arbutus Biopharma have been sold short.Short Interest Ratio / Days to CoverArbutus Biopharma has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in Arbutus Biopharma has recently increased by 8.25%, indicating that investor sentiment is decreasing significantly. News and Social Media2.6 / 5News Sentiment0.76 News SentimentArbutus Biopharma has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Arbutus Biopharma this week, compared to 2 articles on an average week.Search Interest13 people have searched for ABUS on MarketBeat in the last 30 days. This is an increase of 30% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Arbutus Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Arbutus Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.00% of the stock of Arbutus Biopharma is held by insiders.Percentage Held by Institutions43.79% of the stock of Arbutus Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Arbutus Biopharma's insider trading history. Receive ABUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arbutus Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address ABUS Stock News HeadlinesArbutus Biopharma Co. (NASDAQ:ABUS) Short Interest Up 8.3% in SeptemberSeptember 30 at 4:05 AM | americanbankingnews.comArbutus Biopharma (NASDAQ:ABUS) Stock Price Down 2.8%September 27, 2024 | americanbankingnews.comShedding light on a dark secretElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump. October 1, 2024 | Porter & Company (Ad)Arbutus Biopharma Corp Share Price (ABUS.US)September 16, 2024 | lse.co.ukBuy Rating Affirmed for Arbutus Biopharma Amid Positive Legal and Clinical DevelopmentsSeptember 5, 2024 | markets.businessinsider.comArbutus Biopharma to Present at Major Investor Conferences in New YorkSeptember 5, 2024 | msn.comArbutus to Participate in Two Upcoming Investor ConferencesSeptember 3, 2024 | globenewswire.comABUS Sep 2024 4.000 callAugust 18, 2024 | ca.finance.yahoo.comSee More Headlines ABUS Stock Analysis - Frequently Asked Questions How have ABUS shares performed this year? Arbutus Biopharma's stock was trading at $2.50 at the beginning of the year. Since then, ABUS stock has increased by 54.0% and is now trading at $3.85. View the best growth stocks for 2024 here. How were Arbutus Biopharma's earnings last quarter? Arbutus Biopharma Co. (NASDAQ:ABUS) issued its quarterly earnings results on Thursday, August, 1st. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by $0.01. The biopharmaceutical company earned $1.73 million during the quarter, compared to the consensus estimate of $1.54 million. Arbutus Biopharma had a negative net margin of 766.20% and a negative trailing twelve-month return on equity of 66.68%. How do I buy shares of Arbutus Biopharma? Shares of ABUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Arbutus Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arbutus Biopharma investors own include Ballard Power Systems (BLDP), Chiasma (CHMA), Bausch Health Companies (BHC), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), GW Pharmaceuticals (GWPH) and Inovio Pharmaceuticals (INO). Company Calendar Last Earnings8/01/2024Today9/30/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ABUS CUSIPN/A CIK1447028 Webwww.arbutusbio.com Phone(267) 469-0914Fax604-419-3201Employees90Year Founded1992Price Target and Rating Average Stock Price Target$5.25 High Stock Price Target$7.00 Low Stock Price Target$4.00 Potential Upside/Downside+36.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.44) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-72,850,000.00 Net Margins-766.20% Pretax Margin-766.20% Return on Equity-66.68% Return on Assets-50.27% Debt Debt-to-Equity RatioN/A Current Ratio6.56 Quick Ratio6.56 Sales & Book Value Annual Sales$10.06 million Price / Sales72.22 Cash FlowN/A Price / Cash FlowN/A Book Value$0.63 per share Price / Book6.11Miscellaneous Outstanding Shares188,717,000Free Float181,168,000Market Cap$726.56 million OptionableOptionable Beta1.92 Social Links 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report This page (NASDAQ:ABUS) was last updated on 10/1/2024 by MarketBeat.com Staff From Our Partners[Urgent!] Web3 Could Send One Crypto SoaringVenture Capital corporations and blockchain funds are pouring money into Web3 gaming. And there's one littl...Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredFor Elon, I fear the worst is yet to come…Early last year I predicted that there would be a war on Elon Musk. This hateful rhetoric has led to two s...Porter & Company | SponsoredCentral Bank Abandons USDBillionaire investors are pouring capital into gold at rates never seen before… But what these wealthy "fat...True Gold Republic | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCharles Payne’s Secrets to Surviving 2024’s Volatile MarketCharles Payne Wants You Prepared for Q4 Because as we look toward 2025, there's no denying that market vola...Unstoppable Prosperity | SponsoredFDA’s hidden signal greenlights biotech winners — 97% of the timeThe FDA has started to quietly send out a signal … That has given investors a 97% chance of making money. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arbutus Biopharma Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arbutus Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.